Naoya Fujita

List of Publications by Year in Descending Order

120 papers	8,922 citations	56 h-index	93 g-index
123 ext. papers	9,742 ext. citations	7 avg, IF	5.78 L-index

#	Paper	IF	Citations
120	GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.. *Npj Precision Oncology*, **2022**, 6, 16	9.8	1
119	Soluble PD-L1 through alternative polyadenylation works as a decoy in lung cancer immunotherapy. *JCI Insight*, **2021**,	9.9	1
118	Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. *Cancer Science*, **2021**, 112, 2299-2313	6.9	3
117	Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. *Npj Precision Oncology*, **2021**, 5, 32	9.8	6
116	Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. *Cancer Science*, **2021**, 112, 2371-2380	6.9	5
115	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. *Nature Communications*, **2021**, 12, 1261	17.4	14
114	Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. *Oncogene*, **2021**, 40, 5548-5558	9.2	2
113	Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. *Cancer Science*, **2020**, 111, 932-939	6.9	20
112	Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. *Thoracic Cancer*, **2020**, 11, 581-587	3.2	11
111	Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 26245-26253	11.5	50
110	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. *Cancer Chemotherapy and Pharmacology*, **2020**, 86, 517-525	3.5	2
109	Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. *EBioMedicine*, **2019**, 41, 105-119	8.8	60
108	Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. *Journal of Experimental Medicine*, **2019**, 216, 982-1000	16.6	105
107	The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. *Nature Communications*, **2019**, 10, 3604	17.4	65
106	Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses. *Scientific Reports*, **2018**, 8, 9743	4.9	15
105	A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (). *Oncotarget*, **2018**, 9, 33322-33336	3.3	4
104	Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. *Oncotarget*, **2018**, 9, 1641-1655	3.3	16

103	3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer. *Biochemical and Biophysical Research Communications*, **2018**, 501, 527-533	3.4	3
102	Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment. *Journal of Thoracic Oncology*, **2018**, 13, 915-925	8.9	15
101	A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis. *Scientific Reports*, **2017**, 7, 42186	4.9	59
100	Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 752-762	6.1	52
99	Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. *Cancer Science*, **2017**, 108, 696-703	6.9	9
98	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. *Nature Communications*, **2017**, 8, 14768	17.4	197
97	Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. *Molecular Cancer Therapeutics*, **2017**, 16, 2130-2143	6.1	60
96	TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity. *Scientific Reports*, **2017**, 7, 5519	4.9	7
95	Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. *Scientific Reports*, **2017**, 7, 4059	4.9	26
94	Platelet-activating factor podoplanin: from discovery to drug development. *Cancer and Metastasis Reviews*, **2017**, 36, 225-234	9.6	40
93	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. *EBioMedicine*, **2016**, 3, 54-66	8.8	97
92	Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. *Oncotarget*, **2016**, 7, 3934-46	3.3	54
91	Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis. *Nature Communications*, **2015**, 6, 8419	17.4	74
90	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. *Cancer Research*, **2015**, 75, 4188-97	10.1	12
89	Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. *Clinical Cancer Research*, **2015**, 21, 166-74	12.9	145
88	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. *Cancer Discovery*, **2014**, 4, 662-673	24.4	591
87	Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. *International Journal of Cancer*, **2014**, 134, 2605-14	7.5	34
86	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. *Clinical Cancer Research*, **2014**, 20, 5686-96	12.9	227

85	Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance. *Molecular Cancer Therapeutics*, **2014**, 13, 2978-90	6.1	46
84	Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment. *Cancer Medicine*, **2014**, 3, 1595-604	4.8	11
83	Adhesion of pancreatic cancer cells in a liver-microvasculature mimicking coculture correlates with their propensity to form liver-specific metastasis in vivo. *BioMed Research International*, **2014**, 2014, 241571	3	1
82	Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis. *Cancer Science*, **2014**, 105, 983-8	6.9	59
81	Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer. *Pancreas*, **2014**, 43, 1093-100	2.6	9
80	Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. *Cancer Research*, **2013**, 73, 3087-96	10.1	164
79	Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. *PLoS ONE*, **2013**, 8, e73609	3.7	141
78	Successive phosphorylation of p27(KIP1) protein at serine-10 and C terminus crucially controls its potency to inactivate Cdk2. *Journal of Biological Chemistry*, **2012**, 287, 21757-64	5.4	7
77	The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. *Journal of Biochemistry*, **2012**, 152, 407-13	3.1	41
76	Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. *Cancer Science*, **2011**, 102, 2051-7	6.9	43
75	A transmembrane glycoprotein, gp38, is a novel marker for immature hepatic progenitor cells in fetal mouse livers. *In Vitro Cellular and Developmental Biology - Animal*, **2011**, 47, 45-53	2.6	3
74	The novel metastasis promoter Merm1/Wbscr22 enhances tumor cell survival in the vasculature by suppressing Zac1/p53-dependent apoptosis. *Cancer Research*, **2011**, 71, 1146-55	10.1	33
73	Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. *Journal of Biological Chemistry*, **2011**, 286, 2681-8	5.4	24
72	Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L. *Journal of Cell Science*, **2010**, 123, 23-8	5.3	22
71	Insulin-stimulated interaction with 14-3-3 promotes cytoplasmic localization of lipin-1 in adipocytes. *Journal of Biological Chemistry*, **2010**, 285, 3857-3864	5.4	61
70	Mitotic phosphorylation of Aki1 at Ser208 by cyclin B1-Cdk1 complex. *Biochemical and Biophysical Research Communications*, **2010**, 393, 872-6	3.4	5
69	AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. *Oncology Research*, **2010**, 19, 23-33	4.8	53
68	PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. *Molecular Cancer Research*, **2009**, 7, 557-69	6.6	57

67	Centrosomal Aki1 and cohesin function in separase-regulated centriole disengagement. *Journal of Cell Biology*, **2009**, 187, 607-14	7.3	82
66	Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1. *Journal of Cellular Biochemistry*, **2009**, 107, 639-54	4.7	54
65	Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. *Cancer Science*, **2009**, 100, 2060-8	6.9	62
64	TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling. *Cancer Science*, **2008**, 99, 1827-34	6.9	24
63	Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. *American Journal of Pathology*, **2008**, 173, 1566-76	5.8	92
62	Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. *Cancer Research*, **2008**, 68, 5076-85	10.1	217
61	Freud-1/Aki1, a novel PDK1-interacting protein, functions as a scaffold to activate the PDK1/Akt pathway in epidermal growth factor signaling. *Molecular and Cellular Biology*, **2008**, 28, 5996-6009	4.8	49
60	Platelet aggregation in the formation of tumor metastasis. *Proceedings of the Japan Academy Series B: Physical and Biological Sciences*, **2008**, 84, 189-98	4	63
59	Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. *Blood*, **2008**, 112, 1730-9	2.2	56
58	B1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms. *Apoptosis: an International Journal on Programmed Cell Death*, **2008**, 13, 531-42	5.4	66
57	Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. *Journal of Cellular Physiology* , **2007**, 212, 717-28	7	105
56	Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo. *Cancer Research*, **2007**, 67, 9666-76	10.1	53
55	p27Kip1 localization depends on the tumor suppressor protein tuberin. *Human Molecular Genetics*, **2007**, 16, 1541-56	5.6	40
54	Two populations of Thy1-positive mesenchymal cells regulate in vitro maturation of hepatic progenitor cells. *American Journal of Physiology - Renal Physiology*, **2007**, 292, G526-34	5.1	26
53	The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. *American Journal of Pathology*, **2007**, 170, 1337-47	5.8	165
52	Differentiation of lymphatic endothelial cells from embryonic stem cells on OP9 stromal cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 2070-6	9.4	44
51	Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. *Acta Neuropathologica*, **2006**, 111, 563-8	14.3	113
50	Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. *Tumor Biology*, **2005**, 26, 195-200	2.9	185

49	Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. *Molecular Cell*, **2005**, 20, 33-44	17.6	131
48	Stabilization of integrin-linked kinase by binding to Hsp90. *Biochemical and Biophysical Research Communications*, **2005**, 331, 1061-8	3.4	32
47	CXCL13 is an arrest chemokine for B cells in high endothelial venules. *Blood*, **2005**, 106, 2613-8	2.2	43
46	Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells. *Cancer Science*, **2005**, 96, 825-33	6.9	79
45	3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling. *Journal of Biological Chemistry*, **2005**, 280, 40965-73	5.4	74
44	Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. *Molecular and Cellular Biology*, **2005**, 25, 5725-37	4.8	123
43	Human intestinal epithelial cell survival and anoikis. Differentiation state-distinct regulation and roles of protein kinase B/Akt isoforms. *Journal of Biological Chemistry*, **2004**, 279, 44113-22	5.4	64
42	Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. *Journal of Biological Chemistry*, **2004**, 279, 33759-67	5.4	86
41	Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells. *Journal of Biological Chemistry*, **2004**, 279, 38838-43	5.4	81
40	Reconstitution of caspase-3 confers low glucose-enhanced tumor necrosis factor-related apoptosis-inducing ligand cytotoxicity and Akt cleavage. *Clinical Cancer Research*, **2004**, 10, 1894-900	12.9	13
39	Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. *Oncogene*, **2004**, 23, 8552-6	9.2	136
38	Human intestinal epithelial crypt cell survival and death: Complex modulations of Bcl-2 homologs by Fak, PI3-K/Akt-1, MEK/Erk, and p38 signaling pathways. *Journal of Cellular Physiology*, **2004**, 198, 209-22	7	49
37	Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. *Journal of Biological Chemistry*, **2003**, 278, 49254-60	5.4	149
36	Rap1 translates chemokine signals to integrin activation, cell polarization, and motility across vascular endothelium under flow. *Journal of Cell Biology*, **2003**, 161, 417-27	7.3	306
35	Survival-signaling pathway as a promising target for cancer chemotherapy. *Cancer Chemotherapy and Pharmacology*, **2003**, 52 Suppl 1, S24-8	3.5	24
34	Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. *Cancer Science*, **2003**, 94, 15-21	6.9	411
33	Mitochondrial aggregation precedes cytochrome c release from mitochondria during apoptosis. *Oncogene*, **2003**, 22, 5579-85	9.2	68
32	Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. *Journal of Biological Chemistry*, **2003**, 278, 51599-605	5.4	222

31	Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. *International Journal of Cancer*, **2002**, 98, 36-41	7.5	85
30	Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). *Oncogene*, **2002**, 21, 1727-38	9.2	198
29	Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3. *Journal of Biological Chemistry*, **2002**, 277, 39360-7	5.4	77
28	Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. *Molecular and Cellular Biology*, **2002**, 22, 8695-708	4.8	53
27	Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. *Journal of Biological Chemistry*, **2002**, 277, 10346-53	5.4	167
26	Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B. *Journal of Biological Chemistry*, **2002**, 277, 42943-52	5.4	143
25	Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. *Journal of Biological Chemistry*, **2002**, 277, 28706-13	5.4	259
24	Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. *Journal of Biological Chemistry*, **2002**, 277, 26217-24	5.4	67
23	Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. *Circulation Research*, **2002**, 90, 866-73	15.7	286
22	Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro. *Endocrine Journal*, **2002**, 49, 439-47	2.9	14
21	Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. *Cancer Research*, **2002**, 62, 2971-5	10.1	68
20	The cleavage of Akt/protein kinase B by death receptor signaling is an important event in detachment-induced apoptosis. *Journal of Biological Chemistry*, **2001**, 276, 34702-7	5.4	77
19	The Role of Interleukein-11 in the Formation of Bone Metastases **2001**, 67-78		
18	Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis. *Journal of Cellular Physiology*, **2000**, 182, 290-6	7	85
17	In vivo veritas: Bcl-2 and Bcl-X(L)mediate tumor cell resistance to chemotherapy. *Drug Resistance Updates*, **2000**, 3, 149-154	23.2	13
16	Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis. *Journal of Cellular Physiology*, **2000**, 182, 290	7	74
15	NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis. *Journal of Biological Chemistry*, **1999**, 274, 20415-20	5.4	71
14	Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. *Oncogene*, **1999**, 18, 1131-8	9.2	190

13	Interleukin-1 alpha induced cyclooxygenase-2 expression in bone-derived endothelial cells. *Journal of Cellular Physiology*, **1999**, 179, 226-32	7	6
12	p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. *International Journal of Cancer*, **1999**, 83, 790-7	7.5	35
11	Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. *Biochemical and Biophysical Research Communications*, **1999**, 254, 259-63	3.4	49
10	Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. *Oncogene*, **1998**, 16, 693-703	9.2	46
9	Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases. *Oncogene*, **1998**, 17, 1295-304	9.2	152
8	Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. *Journal of Cellular Physiology*, **1998**, 175, 247-54	7	45
7	A novel anti-platelet monoclonal antibody induces mouse platelet aggregation through an Fc receptor-independent mechanism. *Biochemical and Biophysical Research Communications*, **1998**, 242, 250-5	3.4	14
6	Involvement of Bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis. *Biochemical and Biophysical Research Communications*, **1998**, 246, 484-8	3.4	69
5	Aggregation of Thy-1 glycoprotein induces thymocyte apoptosis through activation of CPP32-like proteases. *Experimental Cell Research*, **1997**, 232, 400-6	4.2	17
4	Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-beta and tumor cell factors. *International Journal of Cancer*, **1997**, 71, 422-8	7.5	43
3	A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression. *International Journal of Cancer*, **1996**, 66, 544-50	7.5	18
2	H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption. *Clinical and Experimental Metastasis*, **1995**, 13, 287-95	4.7	30
1	Control of apoptosis and growth of malignant T lymphoma cells by lymph node stromal cells. *Experimental Cell Research*, **1993**, 207, 271-6	4.2	21